Biocon Biologics has a long-term commitment to biosimilars. That is the message that came across clearly from the firm’s chief commercial officer for advanced markets, Matt Erick, as he spoke to Generics Bulletin about how competition in the US biosimilar was a “marathon” that is “not going to be won in the short term.”
Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint
Chief Commercial Officer For Advanced Markets Matt Erick Emphasizes Commitment To Sector
As Biocon Biologics makes multiple moves to position its recently-integrated US biosimilars business for success, the firm’s chief commercial officer for advanced markets, Matt Erick, tells Generics Bulletin that US biosimilar competition is a “marathon” that is “not going to be won in the short term.”
